Sanofi and C4X in $493m licensing deal
13-04-2021
ricochet64 / Shutterstock.com
Mylan Pharmaceuticals has succeeded in getting the Patent Trial and Appeal board (PTAB) to invalidate an injector patent held by French pharmaceutical company Sanofi.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Mylan Pharmaceuticals, Sanofi, patent, PTAB
